Scholar Rock
Clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | $300m | Post IPO Equity |
| Total Funding | 000k | ||
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (25 %) | 22 % | 76 % | - | - | - | 3043 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (564 %) | (677 %) | (405 %) | - | - | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (561 %) | (700 %) | (405 %) | - | - | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 481 % | 576 % | 375 % | - | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Scholar Rock is a biopharmaceutical company focused on developing innovative treatments for diseases by targeting protein growth factors. Operating in the healthcare and biotechnology market, Scholar Rock serves patients and healthcare providers by offering novel therapeutic solutions. The company leverages its unique drug discovery platform to unlock new possibilities in disease treatment, particularly in areas that have been historically overlooked. Scholar Rock's business model revolves around research and development, partnerships, and collaborations with other biopharmaceutical companies and institutions. Revenue is generated through licensing agreements, milestone payments, and eventual product sales. The company is committed to patient-centric approaches and values scientific curiosity and collaboration.
Keywords: biopharmaceutical, protein growth factors, innovative treatments, drug discovery, healthcare, biotechnology, patient-centric, research and development, partnerships, collaborations.